Activation of somatostatin-receptor subtype-2/-5 suppresses the mass, frequency, and irregularity of growth hormone (GH)-releasing peptide-2-stimulated GH secretion in men

What Was Tested

This randomized controlled trial paper looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Octreotide.

Somatostatin antagonizes the stimulatory actions of GHRH and GH-releasing peptides (GHRPs).

However, precisely how the inhibitory susceptibilities of the two secretagogues differ is not clear.

Who Took Part

According to the abstract, 10 men were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, men only.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

What Was Measured

Topics PubMed links to this paper include Growth Hormone-Releasing Hormone, Human Growth Hormone, Octreotide, Oligopeptides and Receptors, Somatostatin.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Octreotide in 10 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2004 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the Octreotide compound page, all human trials.